secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVADEL PHARMACEUTICALS PLC (—)
CIK:        0001012477
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001104659-24-058680
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avadel enters $100M ATM equity facility with Jefferies; terminates prior ADS program
--------------------------------------------------------------------------------

- New Open Market Sale Agreement with Jefferies for up to $100M in ordinary shares at market.
- Replaces previous ADS Sales Agreement terminated after mandatory exchange to ordinary shares on April 15, 2024.
- Prior ADS program raised $13.5M gross ($13.1M net) from 1,112,717 ADSs.
- Jefferies receives 3.0% commission on gross proceeds from sales under new agreement.
- Company may suspend sales at any time; no obligation to sell.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1012477/000110465924058680/0001104659-24-058680-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1012477/000110465924058680/tm2413698d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-058680

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer